375A Concord Road, Concord West NSW 2138
Hepatobiliary (liver and bile duct) and pancreatic cancers in pets are uncommon but are hostile and difficult to manage. In dogs, hepatocellular carcinoma is the most common primary liver tumour, while cholangiocarcinoma, hemangiosarcoma, and metastatic lesions are also seen. In cats, liver tumours are rarer, but bile duct carcinomas and lymphomas can occur. Pancreatic tumors in dogs and cats include insulinomas (islet cell tumours), adenocarcinomas, and gastrinomas, many of which are malignant and prone to metastasis.
Because these tumours are often located deep in the abdomen, clinical signs may be vague or non-specific, leading to delayed diagnosis. Accurate imaging and staging are essential, as many of these cancers behave aggressively and spread to lymph nodes, lungs, or other abdominal organs.
Pets with hepatobiliary or pancreatic tumours may show:
Diagnosis usually includes blood tests, liver function panels, abdominal ultrasound, and CT scans. Biopsies or fine needle aspirates are used to confirm the tumour type. However, conventional imaging often struggles to differentiate between benign nodules, inflammation, and aggressive cancers.
These tumors present unique challenges due to their location and potential for early metastasis. PET-CT combines anatomical and metabolic imaging, giving veterinarians a clearer understanding of tumour activity and spread.
Key benefits include:
We exist to support veterinarians, enabling them to tailor treatment for optimal outcomes. With PET Theranostics, you gain a trusted partner in patient outcomes.
For Vets
Our PET-CT scans give the clearest picture of your pet’s condition, helping your vet determine the best path forward.
For Pet OwnersHepatobiliary and pancreatic cancers affect the liver, bile ducts, or pancreas and are uncommon but often aggressive. In dogs, hepatocellular carcinoma is the most common primary liver tumour, while cholangiocarcinoma, haemangiosarcoma, and metastatic lesions also occur. In cats, bile duct carcinoma and lymphoma are more frequent. Pancreatic tumours such as insulinomas, adenocarcinomas, and gastrinomas can develop in both species and often spread to other organs.
Because these organs are deep within the abdomen, early symptoms are often vague. Common signs include loss of appetite, vomiting, diarrhoea, and weight loss. Some pets may show jaundice (yellowing of the eyes, gums, or skin), abdominal swelling, or weakness. Pets with insulinomas may experience seizures or collapse due to low blood sugar. These non-specific signs make advanced imaging vital for accurate diagnosis.
Diagnosis typically involves blood and liver function tests, abdominal ultrasound, CT scans, and biopsy for histopathology. However, conventional imaging can struggle to distinguish between benign nodules, inflammatory changes, and aggressive cancers. That’s why advanced functional imaging such as PET-CT is increasingly valuable for detecting disease activity and extent more precisely.
PET-CT combines structural and metabolic imaging, revealing not only where a tumour is but how active it is biologically. It detects metastases in the lungs, spleen, lymph nodes, and other organs that ultrasound or CT might miss. PET-CT also differentiates cancerous lesions from benign or regenerative changes in the liver, ensuring vets base their treatment decisions on the clearest possible picture.
PET-CT helps determine whether surgery is appropriate by confirming the extent of local and distant disease. It identifies active tumour regions for precise radiation therapy and tracks metabolic changes during chemotherapy or systemic treatment. Uptake patterns can indicate how aggressive a tumour is, enabling vets to adjust treatment intensity and discuss prognosis realistically with pet owners.
Hepatobiliary and pancreatic cancers are complex, often discovered late, and emotionally distressing for owners. PET Theranostics provides veterinarians with whole-body insight into cancer behaviour, not just its structure. This clarity supports accurate staging, tailored treatment planning, and compassionate guidance for pet owners — ensuring decisions are made with confidence and care.
“To me, Dr. Lurie is Godsent. He is always available to talk. Dr. Lurie gave us all the time on a call on Saturday morning. He didn’t rush us off the phone; he was patient with all our questions. He answered and gave us more information regarding the treatment than what we had even asked for. I don’t know what good I have done in this lifetime to meet such people. Lucky me! Lucky Sambuca! Sensational. Fantastic. Kind. Fabulous. Gentle. Understanding. Relatable”.
Sabeena & David
“From the outset, David explained Toby’s diagnosis and the treatment options not only in simple, understandable terms but, most of all, with incredible empathy. David’s honest and patient approach made our decision to undertake radiotherapy treatment so comfortable. David kept us updated on his progress and continued to reassure us. Over two years on, our little fella is still going strong and is heading towards his 18th birthday – every day is a blessing”
Brian & Sharon PorterTo refer a patient or book a consultation, please call us directly on
02 7238 4190 or use the referral form.
We are a referral-only clinic. Please speak with your Vet about PET Theranostics.
If you have a general enquiry or seek additional clarification about PET-CT/CT scan email us or call our office during normal opening hours.
375A Concord Road, Concord West NSW 2138
Monday-Friday: 8 am-6 pm
Saturday/Sunday – Closed
© 2026 PET Theranostics. All rights reserved. Website by Specialist Vet Marketing